ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Affimed NV

Affimed NV (AFMD)

6.74
-0.36
(-5.07%)
Closed June 17 4:00PM
6.74
0.00
( 0.00% )
Pre Market: 7:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
6.74
Bid
6.55
Ask
7.00
Volume
50
0.00 Day's Range 0.00
2.235 52 Week Range 8.95
Market Cap
Previous Close
6.74
Open
-
Last Trade
48
@
6.34
Last Trade Time
04:53:40
Financial Volume
-
VWAP
-
Average Volume (3m)
734,441
Shares Outstanding
14,933,934
Dividend Yield
-
PE Ratio
-0.95
Earnings Per Share (EPS)
-7.09
Revenue
12.97M
Net Profit
-105.94M

About Affimed NV

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body'... Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Mannheim, Deu
Founded
1970
Affimed NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AFMD. The last closing price for Affimed NV was $6.74. Over the last year, Affimed NV shares have traded in a share price range of $ 2.235 to $ 8.95.

Affimed NV currently has 14,933,934 shares outstanding. The market capitalization of Affimed NV is $100.65 million. Affimed NV has a price to earnings ratio (PE ratio) of -0.95.

AFMD Latest News

U.S. Futures Rise on Fed Decision; Oil Gains on Demand Forecasts

U.S. index futures are trading slightly higher in pre-market on Monday, amidst anticipation of the Fed’s decision on interest rates and Jerome Powell’s press conference, along with...

Affimed Reports First Quarter 2024 Financial Results & Business Update

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2...

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer...

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were...

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.6410.49180327876.18.956.059776396.89739032CS
41.528.62595419855.248.953.820791867.14606648CS
121.5329.36660268715.218.953.87344417.04693658CS
262.73968.45788552864.0018.953.67748696.29112787CS
52-0.56-7.671232876717.38.952.2358176545.63165507CS
156-73.36-91.585518102480.188.12.235119162829.58938208CS
260-25.26-78.937532117.42.235125603241.41700423CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NLSPNLS Pharmaceutics Ltd
$ 0.4201
(183.28%)
62.65M
ASNSActelis Networks Inc
$ 2.64
(129.57%)
7.12M
MYNZMainz BioMed NV
$ 0.7497
(24.95%)
5
MLGOMicroAlgo Inc
$ 4.42
(24.51%)
1.44M
SILKSilk Road Medical Inc
$ 26.80
(23.67%)
10.09k
AWINAERWINS Technologies Inc
$ 1.59
(-52.40%)
28.18k
BIOLBiolase Inc
$ 0.0907
(-38.96%)
4.46M
QMCOQuantum Corporation
$ 0.4769
(-38.86%)
45.14k
AAGRAfrican Agriculture Holdings Inc
$ 0.2407
(-27.50%)
3
YYAIConnexa Sports Technologies Inc
$ 0.4193
(-23.04%)
94.22k
NLSPNLS Pharmaceutics Ltd
$ 0.4201
(183.28%)
62.65M
MBIOMustang Bio Inc
$ 0.919
(22.53%)
22.54M
ASNSActelis Networks Inc
$ 2.64
(129.57%)
7.12M
QLGNQualigen Therapeutics Inc
$ 0.173
(-1.03%)
5.73M
BIOLBiolase Inc
$ 0.0907
(-38.96%)
4.46M

AFMD Discussion

View Posts
Monksdream Monksdream 2 months ago
AFMD under $10
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 3 months ago
03/08/2024 19:50:00 AFMD Affimed N.V. NASDAQ
T1

Affimed Announces 1-for-10 Reverse Stock Split $AFMD https://t.co/Sv8BHKrfBu— Health Stocks News (@health_stocks) March 6, 2024
๐Ÿ‘๏ธ0
Renee Renee 3 months ago
AFMD: effective March 11,2024 a one for 10 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
๐Ÿ‘๏ธ0
glenn1919 glenn1919 4 months ago
AFMD......................................https://stockcharts.com/h-sc/ui?s=AFMD&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 4 months ago
AFMD: A town in Nevada named after a RACE HORSE!!!??? (LOVE-IT!!!!)




"You better STOP that kind of DANCING, Mister!!! Or I will phone HOMELAND DEFENSE!!!"
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 6 months ago
One more good news release and this rockets to 1.35 and better
👍️ 1
befast befast 6 months ago
Unfortunately in the wrong direction. If a rather positive presentation causes a 20+% decrease in share price, imagine what would happen with a negative one. You either stay silent or provide better narrative to rest your case. AFMD management should step in if they believe the presentation was not duly understood
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 6 months ago
Adding itโ€™ll go
๐Ÿ‘๏ธ0
LowFloatLopes LowFloatLopes 6 months ago
In at .3795
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
AFMD new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
AFMD new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
AFMD new 52=week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 11 months ago
AFMD new 52/week low
๐Ÿ‘๏ธ0
mrplmer mrplmer 1 year ago
ASCO starts today. Looking forward to CC tomorrow at 6pm.
๐Ÿ‘๏ธ0
mrplmer mrplmer 1 year ago
We go over $1 today.
๐Ÿ‘๏ธ0
NY1972 NY1972 1 year ago
NK is a slow cooker looking at MDACC data. It takes a lot of convincing before it starts killing, unlike CART. None has died on auto and allo NK as many claimed.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
I am worried about the potential for on-target, off-tumour toxicities as the target is expressed by a number of healthy cells, including HSCs.
๐Ÿ‘๏ธ0
NY1972 NY1972 1 year ago
CD123 is found in CSCs, which are not effectively eliminated by chemotherapy, have the capacity to self-renew, and are capable recapitulating disease. Thus, approaches to target are highly sought and have been tested in preclinical and clinical settings.
๐Ÿ‘๏ธ0
NY1972 NY1972 1 year ago
CD123 is found in CSCs, which are not effectively eliminated by chemotherapy, have the capacity to self-renew, and are capable recapitulating disease. Thus, approaches to target are highly sought and have been tested in preclinical and clinical settings.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
Why CD123? https://finance.yahoo.com/news/affimed-announces-first-patient-successfully-103000071.html
๐Ÿ‘๏ธ0
mrplmer mrplmer 1 year ago
Really. Not my experience.
๐Ÿ‘๏ธ0
turning stone turning stone 1 year ago
Everyone have a happy, healthy and prosperous NEW YEAR



GO AFMD!!!!!!!! 2023 is yours for the asking
๐Ÿ‘๏ธ0
turning stone turning stone 1 year ago
Okay it is time for more shareholders to get on this board and rally for a major up swing. All the signs show an upswing is here.
๐Ÿ‘๏ธ0
turning stone turning stone 2 years ago
There was really NO need for the share price to crash. Even two major analyst agree and moved up the stocks upward value. 65% percent of the open float is owned by institutions who don't seem to have a clue about this company. This is great news for me as I will keep buying more shares as the share price tumbles. I thought the German people were very smart I guess not. We shall see.
๐Ÿ‘๏ธ0
mrplmer mrplmer 2 years ago
oh boy it works
๐Ÿ‘๏ธ0
jjr04001 jjr04001 2 years ago
Bounce coming $AFMD
๐Ÿ‘๏ธ0
stockguard stockguard 2 years ago
Post # 278 below please do not open the PDF file. Someone added some malware to it so DO NOT CLICK ON IT. Sorry that a jerk had to ruin the link.
๐Ÿ‘๏ธ0
Steady_T Steady_T 2 years ago
๐Ÿ‘๏ธ0
mrplmer mrplmer 2 years ago
When is the next event that could move this stock?
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Equity Research
Company Update โ€” December 2, 2021
Biotechnology A?med NV (AFMD)
AFMD: Virtual NDR Highlights Unique Technology, Pipeline Depth, Breadth and Near-Term Value Drivers

https://www.docdroid.net/A28l2M1/wells-fargo-afmd-research-12-2-21-1-pdf
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Affimed: A small-cap biotech with room to run
Bucking the downward trend in biopharma in 2021, Affimed, a small-cap cancer immunotherapy company, has seen its shares actually rise by a healthy 19.8% this year. This tiny immunotherapy company has been able to swim against the current this year due to some truly eye-catching clinical trial data.

Last week, Affimed reported that its lead product candidate AFM13, when combined with a dose of natural killer cells, produced a 100% objective response rate in heavily pre-treated patients with recurrent or refractory CD30-positive lymphomas. AFM13 is thus on track to become the go-to therapy for later-line CD30-positive lymphomas; an indication that ought to be worth around $500 million to $600 million in sales per year.

To put these extremely preliminary revenue figures into context, Affimed currently sports a market cap of just $834 million. That's the key reason why Wall Street thinks this stock could more than double in value over the next 12 months.

Despite its relatively strong year, Affimed's novel anti-cancer platform still comes off as grossly undervalued at these levels. The company could eventually generate billions in sales and it stands out as a top buyout target right now.
https://www.fool.com/investing/2021/11/28/3-best-biopharma-stocks-to-buy-during-this-industr/
๐Ÿ‘๏ธ0
mrplmer mrplmer 3 years ago
Buyout coming soon. Pòtential 10B market.
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Affimed stock jumps 22% after reporting 100% ORR in Phase 1-2 lymphoma study
Nov. 22, 2021 7:43 AM ETAffimed N.V. (AFMD)By: Mamta Mayani
Affimed (NASDAQ:AFMD) soars 21.6% premarket after announcing interim clinical results from Phase 1-2 study, evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimedโ€™s innate cell engager (ICE) AFM13.
As of October 31, 2021, a total of 18 patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas (16 and 2 patients, respectively) were treated with the novel combination of cbNK cells pre-complexed with AFM13.
As of the cutoff date, 16 of 18 patients had achieved an objective response to the treatment according to investigator assessment, with seven complete responses (CR) and nine partial responses.
100% objective response rate (ORR) was observed with a 42% CR rate in 12 patients with Hodgkin Lymphoma, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cbNK cells/kg pre-complexed with AFM13.
No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed.
Treatment was well tolerated with five reported cases of transient infusion related reactions after the monotherapy infusions of AFM13.

https://seekingalpha.com/news/3773189-affimed-stock-jumps-18-after-reporting-100-orr-in-phase-1-2-lymphoma-study
๐Ÿ‘๏ธ0
mrplmer mrplmer 3 years ago
A bump.
๐Ÿ‘๏ธ0
Lynx5100 Lynx5100 3 years ago
Lol What do you call the day before yesterday
๐Ÿ‘๏ธ0
mrplmer mrplmer 3 years ago
Need a breakout.
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Below post on conference was canceled.
Members, Thank you very much for your interest. Our sincere apologies but the doctor has a patient emergency, and we will need to reschedule this call. We will keep you posted. Thank you, Slingshot Insights
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
This one could be interesting for a novice and also the informed, plus it states "AFMD CALL IS FREE FOR ALL" and you are able to add questions before the call. I joined the call that will be in about 2 hours Pacific time-01:00 PM PDT-AFMD-Understanding the potential of AFM13 + NK Cells in CD30-positive lymphomas. Interview Goal
This conversation will discuss the current standard of care for lymphoma patients and the potential of AFM13. We'll ask how meaningful CRs are for patients who failed multiple lines of prior therapies, durability expectations for responses, and what line AFM13 might fall if successful. Sign up below: https://mailchi.mp/slingshotinsights/4-calls-today-on-si-bvhn-jnj-hospital-rev-cycle-cms-patient-surveys-1990719
mailchi.mp
4 Calls Today on SI: NVS, CRIS, CCXI & AFMD (Free to Join)

๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
This morning AFMD Affimed initiated with a Buy at Truist
Truist analyst Srikripa Devarakonda initiated coverage of Affimed with a Buy rating and $10 price target. The analyst cites the company's phase 1 proof of concept data in two rare blood cancers, along with "futility hurdle" that Affirmed passed in pivotal trials, both of which support a peak sales opportunity of about
$500M. Devarakonda further notes the potential near-term upside for Affirmed from updated data from lead drug + NK cell combo likely to be presented at ASH2021.
๐Ÿ‘๏ธ0
mrplmer mrplmer 3 years ago
Anyday now when it goes to $50 I am pretty sure youll be sorry you didnt follow my advise. Nuff said. They arent chasing amyloid plaçque. Sigmar1 receptor hold the key to CNS. Bye bye.
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
mrplmer

Alzheimer's is way to speculative for any company at this stage so I would take a pass on the stock this early on but appreciate the heads up. My father-in-law just was diagnosed with Alzheimer's and I wish there was a biotech play seriously close to some relief for those sufferers and their families.
I follow biotech and invest in the space heavily, so I stay on top of a wide range of bio`s. But Alzheimer's biotech research has not reached that investable point for me yet as there still is too much downside risk in the smaller bio`s research. GLTY with Anavex
๐Ÿ‘๏ธ0
mrplmer mrplmer 3 years ago
If you are not "in" on Anavex then ya better find some powder. They might just have the cure for many CNS diseases. Their Blacarsimine is safe effective and works on Rett syndrome Parkinson's Disease and Dementia. Readouts in the next 2 months. Alzheimer's readout 2nd Q 2022. It agonizes the Sigmar1 receptor and creates cellular homeostasis. IT will be huge. Due Diligence important.
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
From below post:
Affimed: A new way to engage the immune system
Cancer immunotherapy has revolutionized the way oncologists approach the treatment of numerous liquid and solid tumors. Even so, the first generation of checkpoint inhibitors and genetically modified cellular therapies is far from 100% effective. Some of these novel treatments also come with a host of serious and potentially life-threatening side effects that limit their use in certain patient populations.

Affimed, a small-cap immunotherapy company, is trying to change this narrative by engaging the body's own immune system with a platform consisting of so-called "bi-specific antibodies" that active natural killer cells to attack tumor cells.

While the early stage results of the company's lead candidate, known as AFM13, have been impressive as a monotherapy from both an efficacy and safety standpoint, Affimed is also evaluating this therapy in combination with cord blood-derived natural killer cells, as well as checkpoint inhibitors. Wall Street, for its part, thinks this single biologic therapy could rake in well over $600 million at its peak.

Where do things stand now? Affimed is hoping to file its first regulatory application for AFM13 as a monotherapy indicated for patients with relapsed/refractory peripheral T-cell lymphoma. If things go according to plan, the biotech's first therapy could be on the market by perhaps 2023. Before then, however, there is a strong possibility that Affimed simply gets bought out. Big pharma has been on the hunt of late for early-stage cancer immunotherapy companies with unique assets, and Affimed fits that mold to a tee.

All told, Affimed's shares appear to be a downright steal at these levels. The company's market cap of $707 million arguably doesn't properly represent the promise of its anticancer platform -- even on a risk-adjusted basis. Affimed, after all, has already presented strong early stage results for its novel immunotherapy platform. Another major clinical update is reportedly slated to happen at a medical conference in the fourth-quarter of this year, according to the company's last quaterly update. Aggressive investors, therefore, might be wise to consider buying this undervalued biotech stock soon.
https://www.fool.com/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
2 Biotech Stocks Set to Go Supernova Soon
https://www.fool.com/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Affimed (NASDAQ:AFMD) Receives $13.75 Average PT from Brokerages
Posted by Max Byerly on Jul 26th, 2021
Affimed (NASDAQ:AFMD) has been given an average rating of โ€œBuyโ€ by the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $13.75.
https://www.tickerreport.com/banking-finance/7687643/affimed-nasdaqafmd-receives-13-75-average-pt-from-brokerages.html
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Advancing Immuno-Oncology by believing in the potential of the immune system to restore patientsโ€™ innate ability to fight cancer

https://www.rdworldonline.com/advancing-immuno-oncology-by-believing-in-the-potential-to-restore-patients-ability-to-fight-cancer/
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Affimed: Remaining Bullish Despite Study Discontinuation
https://seekingalpha.com/article/4438388-affimed-remaining-bullish-despite-study-discontinuation
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2021 Results - Earnings Call Transcript
https://seekingalpha.com/article/4437496-affimed-n-v-afmd-ceo-adi-hoess-on-q1-2021-results-earnings-call-transcript
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
$AFMD June presentation https://www.affimed.com/wp-content/uploads/Affimed-N.V._CP_June-2021.pdf
๐Ÿ‘๏ธ0
stockguard stockguard 3 years ago
Wells Fargo Says
Affimed is an immune-oncology researcher in the biopharma world, looking into new therapies for cancer patients. The companyโ€™s โ€˜redirected optimized cell killingโ€™ (ROCK) platform is used to develop innate cell engagers capable of reactivating the patientโ€™s own immune cells to combat tumors. The company has 6 separate programs in its development pipeline, most in the preclinical stage of research. The companyโ€™s focus is on the treatment of hematological and solid tumors.

Of Affimedโ€™s drug candidates, AFM13 is the first to have reached the clinical trial stage. The candidate has trials ongoing for the treatment of peripheral T cell lymphoma and CD30-postive T cell lymphoma, as well as transformed mycosis fungoides. Other lines of research are in earlier phases of development. AMF13 is a CD16A-based innate cell engager, and has shown promise of some therapeutic efficacy as well as a favorable safety profile.

In March, Affimed announced that it will be continuing REDIRECT, a Phase 2 study of AFM13 as a treatment for CD30-postivie T cell lymphoma. So far, the study has shown some anti-tumor response in both Cohort A and Cohort B of the patient base. Affimedโ€™s recent program update also showed significant progress with AFM24, the companyโ€™s second most advanced program, now in a Phase 1 trial of its efficacy against solid tumors.

In his report on Affimed for Well Fargo, analyst Nick Abbott gives the stock an Overweight (i.e. Buy) rating and a $18 price target that indicates a potential for 62% upside in the year ahead.

Backing his stance, Abbott writes, โ€œOur Overweight rating on AFMD reflects our view on AFMDโ€™s approach to immuno-oncology (IO) with focus on the ROCK platform of innate cell engaging bispecific antibody development as a monotherapy, in combination with checkpoint inhibitors and in combination with cell therapy. Positive interim analysis of the registration-directed REDIRECT trial of AFM13 provides validation of the ROCK platform, in our view.โ€

Wall Streetโ€™s analysts are unanimous here, giving the stock 5 positive reviews in recent weeks for a Strong Buy consensus rating. The shares are priced at $10.42 and their $14 average target implies ~25% one-year upside.
https://www.tipranks.com/news/article/wells-fargo-says-these-2-stocks-could-spike-over-60-from-current-levels
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock